PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jahaLink to Publisher's site
 
J Am Heart Assoc. 2013 June; 2(3): e000134.
Published online 2013 June 21. doi:  10.1161/JAHA.113.000134
PMCID: PMC3698773

Deficiency of TDAG51 Protects Against Atherosclerosis by Modulating Apoptosis, Cholesterol Efflux, and Peroxiredoxin‐1 Expression

Abstract

Background

Apoptosis caused by endoplasmic reticulum (ER) stress contributes to atherothrombosis, the underlying cause of cardiovascular disease (CVD). T‐cell death‐associated gene 51 (TDAG51), a member of the pleckstrin homology‐like domain gene family, is induced by ER stress, causes apoptosis when overexpressed, and is present in lesion‐resident macrophages and endothelial cells.

Methods and Results

To study the role of TDAG51 in atherosclerosis, male mice deficient in TDAG51 and apolipoprotein E (TDAG51−/−/ApoE−/−) were generated and showed reduced atherosclerotic lesion growth (56±5% reduction at 40 weeks, relative to ApoE−/− controls, P<0.005) and necrosis (41±4% versus 63±8% lesion area in TDAG51−/−/ApoE−/− and ApoE−/−, respectively; P<0.05) without changes in plasma levels of lipids, glucose, and inflammatory cytokines. TDAG51 deficiency caused several phenotypic changes in macrophages and endothelial cells that increase cytoprotection against oxidative and ER stress, enhance PPARγ‐dependent reverse cholesterol transport, and upregulate peroxiredoxin‐1 (Prdx‐1), an antioxidant enzyme with antiatherogenic properties (1.8±0.1‐fold increase in Prdx‐1 protein expression, relative to control macrophages; P<0.005). Two independent case–control studies found that a genetic variant in the human TDAG51 gene region (rs2367446) is associated with CVD (OR, 1.15; 95% CI, 1.07 to 1.24; P=0.0003).

Conclusions

These findings provide evidence that TDAG51 affects specific cellular pathways known to reduce atherogenesis, suggesting that modulation of TDAG51 expression or its activity may have therapeutic benefit for the treatment of CVD.

Keywords: apoptosis, arteriosclerosis, atherosclerosis, cardiovascular diseases

Introduction

Cardiovascular disease (CVD) is an acute clinical manifestation of atherothrombosis that accounts for the majority of deaths in North America.1 A number of risk factors are known to accelerate CVD, including hypercholesterolemia, smoking, diabetes, hypertension, hyperhomocysteinemia, and obesity. Despite the diversity of these risk factors, the development and progression of atherosclerotic lesions is remarkably similar. Endothelial cell dysfunction and the accumulation of cholesterol‐rich lipoproteins in the vessel wall are early events in atherogenesis, resulting in the recruitment of circulating monocytes, their adhesion to the endothelium, their subsequent differentiation into macrophages, and the accumulation of lipid to form foam cells.2 In humans, these fatty streaks can progress to more advanced lesions characterized by a lipid‐rich necrotic core and a fibrous cap consisting of smooth muscle cells and collagen.

The acute clinical manifestations of atherosclerosis result from plaque rupture, thrombus formation, and vessel occlusion.3 Apoptotic cell death is a key feature of unstable plaques4 and is induced by a number of cellular stress pathways, including oxidative and endoplasmic reticulum (ER) stress.57 The distribution of cell death is heterogeneous within advanced lesions, but is most prominent in the lipid‐rich necrotic core that contains a high density of macrophages. Apoptotic cell death increases the risk of plaque rupture by decreasing the number of viable smooth muscle cells necessary for collagen production and compromising the structural integrity of the fibrous cap following release of matrix metalloproteinases from dead macrophages.8 Furthermore, plaque thrombogenicity is enhanced because lesion‐resident cells undergoing apoptosis express active cell surface tissue factor (TF),9 the major physiological initiator of the coagulation cascade.10 Previous studies have demonstrated that the absence of specific proapoptotic factors such as Bax11 or Rb12 decreases macrophage apoptosis as well as necrotic core size in hyperlipidemic mice. Consistent with these findings, a reduction in apoptosis and plaque necrosis was observed in advanced atherosclerotic lesions from ApoE−/− mice deficient in the ER stress effector CHOP.5

TDAG51 is a member of the pleckstrin homology‐like domain family having proapoptotic characteristics.13 Furthermore, TDAG51 is induced by ER stress,1416 and its overexpression in human vascular endothelial cells induces apoptotic cell death by disrupting cytoskeletal structure and impairing cell adhesion.15 Conversely, deficiency of TDAG51 contributes to apoptosis resistance and growth dysregulation in metastatic melanomas in vivo.17 TDAG51 can also regulate energy metabolism by modulating adipogenesis and hepatic lipogenesis, which correlates with mature‐onset metabolic disease.18 Several lines of evidence implicate TDAG51 in atherosclerotic lesion development. TDAG51 expression is increased in lesion‐resident macrophages and endothelial cells during all stages of atherogenesis.6,15 Furthermore, TDAG51 mRNA is significantly increased in cultured human vascular endothelial cells following exposure to athero‐prone waveform stimulation.19 Although these findings suggest that TDAG51 contributes to the atherosclerotic process, it is currently unknown if TDAG51 is causally related to atherogenesis or if its mechanism of action stems from its previously described role as a proapoptotic factor.

In this report, we investigated whether loss of TDAG51 alters the development and progression of atherosclerosis by crossing TDAG51−/− mice20 with ApoE−/− mice, an established hyperlipidemic mouse model of accelerated atherosclerosis.21 Our findings provide the first in vivo evidence that deficiency of TDAG51 reduces atherosclerotic lesion growth. Furthermore, such inhibition of atherogenesis because of TDAG51 deficiency likely involves the action of PPARγ on specific cellular targets and pathways that are known to affect atherosclerotic lesion development and progression.

Methods

Mice and Dietary Conditions

ApoE−/− mice were obtained from the Jackson Laboratory (Bar Harbor, ME). TDAG51‐deficient (TDAG51−/−) mice have been previously described.20 TDAG51−/− (knockout [KO]) mice were backcrossed >9 generations onto a C57BL/6 background. TDAG51‐deficient mice were crossbred with TDAG51+/+/ApoE−/− mice (also on a C57BL/6 background) to generate TDAG51−/−/ApoE−/− double‐knockout (dKO) mice as well as ApoE−/− littermate controls. Given previous studies showing that the PPARγ ligand effect on atherosclerosis is sex specific toward male mice,22 only male mice were used in this study. Mice were housed with free access to regular chow diet. All experimental procedures using mice were approved by the McMaster University Animal Research Ethics Board.

Mouse Genotyping Using Polymerase Chain Reaction

Polymerase chain reaction (PCR) was performed to assess the presence of wild‐type (WT) and/or disrupted TDAG51 alleles using the following primers: WT 1, WT 2, TDAG51 KO 1, and TDAG51 KO 2. PCR‐amplified products (1‐kbp band, wild‐type TDAG51; 400‐bp band, disrupted TDAG51) were analyzed by agarose gel electrophoresis (AGE). ApoE genotyping was confirmed using primers ApoE 1, ApoE 2, and ApoE 3. PCR‐amplified products (155‐bp band, wild‐type ApoE; 245‐bp band, disrupted ApoE) were analyzed by AGE.

Primers used in this study were WT 1 (5′‐CCG CAG CAC CTC CAA CTC TGC CTG‐3′), WT 2 (5′‐GTC TTC AAA TAC AAT GAA AGA GTC G‐3′), TDAG51 KO 1 (5′‐AAA TGG AAG TAG CAC GTC TCA CTA GTC TCG‐3′), TDAG51 KO 2 (5′‐AGA GCA GCC GAT TGT CTG TTG TGC CCA GTC‐3′), ApoE 1 (5′‐GCC TAG CCG AGG GAG AGC CG‐3′), ApoE 2 (5′‐TGT GAC TTG GGA GCT CTG CAG C‐3′), and ApoE 3 (5′‐GCC GCC CCG ACT GCA TCT‐3′).

Quantitative RT‐PCR

Gene‐specific primer sets for mouse PPARα, ‐γ, and ‐δ were designed by the Genescript Primer Design Program (http://www.genescript.com). Primer sets for mouse ABCA1 and ABCG1 were purchased from Qiagen (Germantown, MD). Sequences for MCP‐1 and TNFα primers were reported previously.23 qRT‐PCR reactions were carried out using SYBR Green, and data was analyzed by the [increment][increment]C(T) method, normalized to 18s, and shown as fold‐change in expression.

Primers used in this study were MCP‐1 forward primer (5′‐CTC AGC CAG ATG CAG TTA ACG‐3′), MCP‐1 reverse primer (5′‐GGG TCA ACT TCA CAT TCA AAG G‐3′), TNFα forward primer (5′‐TCT CAG CCT CTT CTC ATT CCT‐3′), TNFα reverse primer (5′‐ACT TGG TGG TTT GCT ACG AC‐3′), LXRα forward primer (5′‐GGA GGC AAC ACT TGC ATC CT‐3′), and LXRα reverse primer (5′‐AGG GCT GTA GGC TCT GCT GA‐3′).

Isolation of Peritoneal Macrophages

Wild‐type C57BL/6 and TDAG51−/− mice were injected intraperitoneally with 500 μL of 80 μg/mL concanavalin A.7 Peritoneal macrophages were harvested 3 days postinjection. Macrophages were cultured in RPMI‐1640 containing 10% FBS and 50 ng/mL macrophage colony stimulating factor.

Isolation and Culture of Mouse Lung Microvascular Endothelial Cells

Mouse lung microvascular endothelial cells (MLECs) were isolated and cultured using a protocol derived from previous studies24 and Miltenyi Biotec (Auburn, CA). Briefly, mouse lung cells were incubated with MACS LSEC (CD146) microbeads (130‐092‐007, Miltenyi Biotec) and subsequently eluted from a MACS Separation LS column (130‐042‐401, Miltenyi Biotec). MLECs were cultured in endothelial cell growth medium (CC‐3121; Lonza, Walkersville, MD).

Measurement of Total Cholesterol, Triglyceride, and Glucose

Plasma total cholesterol was measured using an Infinity cholesterol measurement kit (Thermo Electron Corporation, Melbourne, Australia). Triglyceride and glucose levels in mice plasma were determined similarly to the above described cholesterol assay (Thermo Electron Corporation).

Macrophages were pretreated in the presence or absence of 10 μmol/L GW9662 in FBS‐deficient media for 4 hour before incubation with acetyl‐LDL (50 μg/mL) or acetyl‐LDL+GW9662 (10 μmol/L) for 24 to 48 hours. Cellular lipids were isolated via Bligh and Dyer chloroform:methanol extraction25 with subsequent assessment of total and free cholesterol levels using Cholesterol E and Free Cholesterol E kits (Wako Pure Chemical Industries, Ltd, Osaka, Japan). Lipid content was normalized against cellular protein and the data expressed as fold‐change.

Measurement of Cholesterol Efflux in Peritoneal Macrophages

HDL/APOA1‐dependent cholesterol efflux to the medium was determined as described previously.26 Peritoneal macrophages isolated from TDAG51−/− and wild‐type C57BL/6 mice were plated at a density of 5×105 cells/well and loaded with 1 μCi/mL [3H]cholesterol (PerkinElmer Life Sciences) in RPMI‐1640 media containing 5% LPDS for 48 hours. To equilibrate cholesterol pools, cells were washed twice in media containing 2% fatty acid–free BSA and cultured overnight in the same media. Media were removed, and cells were incubated for 1 to 5 hours in media containing 0.2% BSA in the absence or presence of 40 μg/mL HDL. Following incubation, radioactivity of culture supernatants and cell lysates was measured by liquid scintillation. Results were normalized to total cellular protein content and expressed as the percentage of radioactivity in the medium divided by the total radioactivity in the cells and medium.

Lactate Dehydrogenase Release Assay

Peritoneal macrophages and MLECs were incubated in the presence or absence of 2.5 μg/mL tunicamycin, 100 nmol/L thapsigargin, or 10 μmol/L 7‐ketocholesterol (7‐KC) for 24 hours. Lactate dehydrogenase release was measured using a Cytotoxicity Detection Kit (Roche, Laval, Canada).

Detection of Superoxide

Superoxide levels in cells were measured using fluorescent‐dye dihydroethidium (Invitrogen, Carlsbad, CA) as previously described.16 Fluorescence intensity is reported as relative fluorescence units (RFU).

Measurement of Mouse Plasma Lipid Profiles Using FPLC

Mouse plasma was fractionated into lipid components using gel filtration‐fast protein liquid chromatography (FPLC), as described previously.27

Tissue Sample Preparation

Following perfusion–fixation with 10% neutral buffered formalin,6,28 hearts (including the aortic roots) were cut transversely and embedded in paraffin. Serial sections, 4 μm thick, were cut starting from the aortic root origin and collected for measurement of lesion size (hematoxylin/eosin staining) and immunohistochemical analyses.29 In each mouse, the atherosclerotic lesion area was measured in 5 sections separated by 80 μm (ie, within 320 μm from the aortic valve).29 The lesion was traced manually and measured using computer‐assisted image analysis equipment (Olympus BX41 microscope, Olympus DP70 CCD camera, and ImagePro Plus software). Lesion size is expressed as the mean of 5 sections. Therefore, this number is directly proportional to the volume of the lesions in the first 320 μm of the ascending aorta.

Immunohistochemical Analysis

Immunohistochemical staining of atherosclerotic lesions was performed as described previously.6,29 Sections were counterstained with hematoxylin. Human carotid arteries were obtained at the time of endarterectomy from consenting patients. The protocol was approved by the institutional ethics review boards of Hamilton Health Sciences and St. Joseph's Healthcare. Tissue was fixed with formalin and embedded in paraffin. Double immunofluorescence was performed on the sections as described previously.29

Antibodies used for immunostaining were anti‐GRP78 (sc‐1050; Santa Cruz, CA), anti‐cleaved caspase‐3 (9661; Cell Signaling, Danvers, MA), anti‐Mac‐3 (55322; BD Pharmingen, San Diego, CA), anti‐KDEL (SPA‐827; Enzo Life Sciences, Farmingdale, NY), anti‐PDI (SPA‐891; Enzo Life Sciences), anti‐PPARγ (07‐466; Upstate, Billerica, MA), anti‐Prdx‐1 (SA‐356; Enzo Life Sciences), anti‐SMA (A2547; Sigma, St. Louis, MO), and anti‐CD3 (A0452; DAKO, Glostrup, Denmark). Nonspecific immunostaining was not detected in control sections. Controls consisted of nonimmune IgG as the primary antibody or the secondary antibody alone. A TACS 2TdT In Situ Apoptosis Detection Kit (Trevigen, Gaithersburg, MD) was used for TUNEL staining. Collagen was stained with Masson's trichrome (HT‐15‐1KT; Sigma).

Immunostaining was quantified by extracting the blue component of the RGB image, thresholding for the staining, and measuring the stained area as well as the total area of the lesion (by manual tracing) using ImagePro 6.3 software. Results are expressed as a percentage of the total lesion area.

Identification of Insulin and Glucagon in β Cells From Islets of Langerhans

Pancreatic tissue from 25‐week‐old TDAG51+/+/ApoE−/− or TDAG51−/−/ApoE−/− mice was immunostained for insulin (red) or glucagon (green). In brief, paraffin sections were deparaffinized and blocked with 5% normal goat serum (Vector, Burlingame, CA). Subsequently, sections were incubated with mouse anti‐insulin antibody cocktail (MS‐1379; Thermo Fisher, Fremont, CA) diluted 1:200, followed by rabbit anti‐glucagon ready‐to‐use antibody (Zymed, San Francisco, CA), for 1 hour each. A mix of goat anti‐rabbit Alexa 488 and goat anti‐mouse Alexa 594 (Molecular Probes, Eugene, OR), diluted 1:200, was applied for 30 minutes. Slides were mounted with Permafluor (Thermo Fisher) and viewed in a Zeiss Axioplan fluorescence microscope.

Indirect Immunofluorescence of Endogenous TDAG51 Expression in Lesion‐Resident Macrophages

Six‐week‐old TDAG51+/+/ApoE−/− mice were placed on control chow diet for 25 weeks. Mice were euthanized, and hearts containing the aortic roots were removed, embedded in paraffin, sectioned, and immunostained. Primary antibodies were detected using either Alexa 488 or Alexa 594 donkey anti‐goat IgG (Molecular Probes). A Carl Zeiss LSM510 laser‐scanning confocal microscope was used to examine endogenous TDAG51 localization.

Collagen Content in Atherosclerotic Lesions From Aortic Roots

Six‐week‐old TDAG51+/+/ApoE−/− or TDAG51−/−/ApoE−/− mice were placed on control chow diet for 25 weeks. Hearts containing aortic roots were removed, embedded in paraffin, serially sectioned, and stained with Masson's trichrome. For quantification of collagen content, 1 section per mouse, close to the aortic root origin, was assessed. The amount of collagen was quantified by thresholding for the blue color using Image Pro software, and collagen area is expressed as a percentage of the total lesion area in that section.

En Face Oil Red O Staining of Mouse Aortas

Unopened aortas were stained with Oil Red O. Aortas were then opened longitudinally, and the stained area was measured as percentage of the total aorta.

Case–Control Genetic Association Studies

The association between CVD and single‐nucleotide polymorphisms (SNPs) in a 56‐kbp region (chromosome 12, positions 74 680 495 to 74 736 823) that included the entire TDAG51 gene (chromosome 12, positions 74 705 495 to 74 711 823) and 25 kbp upstream and downstream of the gene was examined in 2 case–control studies. We evaluated results from the CVD case–control study published by the Wellcome Trust Case–Control Consortium (WTCCC).30 The WTCCC study included 2000 cases with documented CVD and 3000 controls; all cases and controls were white. The University of California, San Francisco (UCSF) case–control study included 731 myocardial infarction patients and 797 healthy controls, collected by investigators at the UCSF Genomic Resource in Arteriosclerosis.31 The number of cases and controls who were successfully genotyped is reported for each genotype group in Tables 3 and 4.

Statistical Analysis

Experimental values are presented as mean±standard error (SE). Unless otherwise noted, statistical comparisons for all experiments were performed using Mann–Whitney (for 2 groups) and Kruskal–Wallis (for >2 groups) tests. Statistical comparisons for en face Oil Red O staining of mouse aortas and Oil Red O staining of peritoneal macrophages were performed using the unpaired Student t test and ANOVA. P<0.05 was considered statistically significant for all tests.

The association between SNPs and myocardial infarction was performed by logistic regression analysis that adjusted for age and sex. A combined analysis of the results from the UCSF study and the WTCCC study was carried out using the fixed‐effects Mantel–Haenszel method that combined odds ratios across these studies; homogeneity of the odds ratios was assessed by the Breslow–Day test.

Results

Loss of TDAG51 Reduces Atherosclerotic Lesion Development and Progression

To investigate the role of TDAG51 in atherosclerotic lesion development, we generated TDAG51−/−/ApoE−/− double‐knockout male mice (dKO), as well as TDAG51+/+/ApoE−/− littermate/sex controls (Figure 1). To focus on the effect of TDAG51 deficiency, male mice were maintained on a control chow diet, as opposed to a high‐fat chow diet, to minimize the potential contribution of obesity and insulin resistance32 to atherosclerotic lesion development and necrosis.

Figure 1.
Identification of TDAG51−/−/ApoE−/− mice. Mouse genomic DNA was amplified by PCR using specific primer sets, and the PCR products were separated on agarose gels to identify mice containing the wild‐type TDAG51 allele ...

Total plasma lipids, glucose, and inflammatory cytokines, as well as aortic atherosclerotic lesion size and composition, were analyzed at 25 and 40 weeks of age. No significant differences in total plasma cholesterol or triglycerides were observed between dKO and ApoE−/− mice (Figure 2A and and2B).2B). Consistent with these findings, plasma lipid profiles were indistinguishable between these groups at 25 weeks of age (Figure 2C). No significant changes in body weight (data not shown), plasma glucose level (Figure 2D), or morphology of pancreatic β cells from the islets of Langerhans (Figure 3) were observed in dKO and ApoE−/− mice.

Figure 2.
Effect of TDAG51 deficiency on plasma lipoproteins and glucose in ApoE−/− mice. TDAG51−/−/ApoE−/− mice (dKO) and ApoE−/− control mice were fed standard chow diets for 25 or 40 weeks (n=8 ...
Figure 3.
Identification of insulin and glucagon in β cells from the islets of Langerhans. Representative sections from 5 mice per group of pancreatic tissue from 25‐week‐old TDAG51+/+/ApoE−/− (ApoE−/−) or ...

As reported previously,6,15 TDAG51 is expressed in lesion‐resident macrophages and endothelial cells from 25‐week‐old ApoE−/− mice (Figure 4). However, this pattern of expression was absent in atherosclerotic lesions from dKO mice. Paraffin sections from the aortic root of dKO and ApoE−/− mice at 25 or 40 weeks of age were stained with hematoxylin and eosin to assess lesion growth and gross cellular morphology (Figure 5A). Lesion area was reduced by 50% at 25 weeks (0.70±0.14 versus 1.40±0.27 ×105 μm2, P=0.038) and 56% at 40 weeks (2.45±0.29 versus 5.52±0.63 ×105 μm2, P=0.0043) (Figure 5B) in dKO mice, compared with ApoE−/− mice. In addition, en face Oil Red O (ORO) lipid staining (Figure 5C) was decreased by 75% in the aortas of dKO mice at 40 weeks of age (8.9±4.4% versus 2.0±0.9%, P<0.005). Although not significant at 25 weeks, mean necrotic core size was reduced by >50% in the dKO mice compared with ApoE−/− mice (0.12±0.06 versus 0.26±0.06 ×105 μm2, P=0.26) (Figures (Figures5D5D and and5E),5E), consistent with the reduction in atherosclerotic lesion size. Normalization to lesion area showed a 14.4±3.8% necrotic core area in the dKO mice, compared to 17.5±2.1% in ApoE−/− mice at 25 weeks. At 40 weeks mean necrotic core size in dKO mice was significantly smaller than in ApoE−/− mice (1.0±0.1 versus 3.5±0.6 ×105 μm2, P<0.005; Figure 5D and and5E),5E), and when normalized to lesion area, necrotic cores of dKO mice were reduced compared with ApoE−/− controls (41±4% versus 63±8%, P<0.05). Thus, in the setting of a normal chow diet, ApoE−/− mice lacking TDAG51 exhibited reduced atherosclerotic lesion growth and necrosis.

Figure 4.
Expression of TDAG51 in atherosclerotic lesions. Six‐week‐old TDAG51+/+/ApoE−/− and TDAG51−/−/ApoE−/− mice were fed control chow diet for 25 weeks. Mice were euthanized, and hearts containing ...
Figure 5.
Effect of TDAG51 deficiency on atherosclerotic lesions in ApoE−/− mice. TDAG51−/−/ApoE−/− mice (dKO) and ApoE−/− control mice were fed standard chow diets for 25 or 40 weeks (n=8 to 9 per ...

Immunohistochemical analysis revealed that dKO and ApoE−/− mice developed fatty streaks and mature atherosclerotic lesions, consisting of macrophages and smooth muscle cells, in the atherosclerotic cap region (Figure 6). However, at 25 and 40 weeks of age, there were no significant differences in the content of either macrophages or smooth muscle cells in the lesions of dKO and ApoE−/− mice (Figure 6 and Table 1). In support of the en face lipid staining (Figure 5C) and increased necrotic core size (Figure 5D and and5E),5E), cholesterol crystals were prevalent in the necrotic core regions of the 25‐week‐old ApoE−/− mice (Figure 5D). Collagen content in the lesions, as measured by Masson's trichrome staining, showed high intralesion variability and did not differ significantly between the ApoE−/− and dKO groups (23.4% versus 27.9%, P=0.48; Figure 7). However, at 40 weeks dKO mice exhibited less vascular calcification, as assessed by von Kossa staining, compared with ApoE−/− mice (Figure 8). Inflammatory cytokines are known to influence several cellular processes that accelerate atherosclerotic lesion growth and stability.33 However, loss of TDAG51 had no significant effect on plasma levels of proinflammatory cytokines, including IL‐12, TNF‐α, or MCP‐1, up to 40 weeks (Table 2). These data suggest the decrease in lesion area was primarily a result of reduction in necrotic core size.

Table 1.
Lesion Composition of TDAG51−/−/ApoE−/− and ApoE−/− Mice
Table 2.
Plasma Inflammatory Marker Levels
Figure 6.
Morphological assessment of atherosclerotic lesions from TDAG51−/−/ApoE−/− (dKO) and ApoE−/− control mice. Atherosclerotic lesions from aortic roots of mice fed control chow diet for 25 or 40 weeks (n=8 ...
Figure 7.
Collagen content in atherosclerotic lesions. Six‐week‐old TDAG51+/+/ApoE−/− (ApoE−/−) and TDAG51−/−/ApoE−/− (dKO) mice were fed control chow diet for 25 weeks. Hearts containing ...
Figure 8.
Calcification in atherosclerotic lesions. TDAG51+/+/ApoE−/− (ApoE−/−) and TDAG51−/−/ApoE−/− (dKO) mice were fed chow diet for 40 weeks. Hearts containing aortic roots were removed, sectioned, ...

TDAG51 Deficiency Is Cytoprotective Against ER Stress and Oxidative Stress

TDAG51 expression is increased by ER stress and causes detachment‐induced apoptotic cell death when overexpressed.15,34 Recent studies have reported that reducing ER stress by treatment with the small chemical chaperone 4‐PBA35 or by genetic ablation of CHOP5 attenuates apoptosis, plaque necrosis, and atherogenesis in ApoE−/− mice. To investigate whether the absence of TDAG51 decreases apoptosis in vivo, atherosclerotic lesions were stained for TUNEL and activated caspase‐3.6 TUNEL staining as well as activated caspase‐3 staining was reduced in the necrotic core of advanced lesions from dKO mice, compared with ApoE−/− mice (Figure 9A). In support of these findings, we observed that TDAG51−/− peritoneal macrophages (Figure 9B) were resistant to cell death induced by ER stress and oxidative stress.

Figure 9.
TDAG51 deficiency reduces cell death in atherosclerotic lesions and peritoneal macrophages. TDAG51−/−/ApoE−/− (dKO) or ApoE−/− mice were placed on control chow diet for 25 weeks. A, Representative images ...

TDAG51 Negatively Regulates the Expression of PPARγ and Its Downstream Targets

To provide further mechanistic insight into the antiatherogenic effects of TDAG51 deficiency, we investigated the expression of PPARγ because of its involvement in modulating various pathways contributing to atherogenesis, such as inflammation, lipid metabolism, and oxidative stress. Furthermore, we have previously observed an inverse correlation between TDAG51 and PPARγ expression in 3T3‐L1 cells.18 Prior studies have demonstrated the expression of PPARγ in lesion‐resident macrophages from LDLR−/− mice.36 To determine whether deficiency of TDAG51 alters the expression of PPARγ in lesional macrophages, paraffin sections from the aortic roots of chow‐fed dKO and ApoE−/− mice after 15 or 25 weeks were immunostained for PPARγ (Figure 10A). Intense nuclear staining for PPARγ was observed in lesion‐resident macrophages from dKO mice compared with ApoE−/− mice. As a positive control, nuclear staining for PPARγ was observed in adipocytes from dKO and ApoE−/− mice (Figure 10B). Again, the intensity of nuclear staining for PPARγ was increased in adipocytes from dKO mice as well as in cultured TDAG51−/− macrophages (Figure 10C). Furthermore, TDAG51−/− peritoneal macrophages exhibited increased mRNA expression of PPARγ (2.8±0.5‐fold, P<0.05) and its target gene, LXRα (1.9±0.3‐fold, P<0.05), as well as PPARγ‐inducible gene ABCG1 (1.7±0.1‐fold, P<0.05), but not ABCA1, compared with wild‐type macrophages (Figure 11).

Figure 10.
TDAG51 deficiency increases PPARγ expression and nuclear localization in lesion‐resident macrophages. A, TDAG51−/−/ApoE−/− (dKO) or ApoE−/− mice were placed on control chow diet for 15 or ...
Figure 11.
Detection of PPARγ and its target genes in peritoneal macrophages. Total RNA was isolated from male TDAG51−/− or C57BL/6 (C57) peritoneal macrophages and mRNA expression assessed by qRT‐PCR. Data were normalized to 18s, ...

Consistent with these findings, reintroduction of TDAG51 using a retrovirus expression construct caused a significant reduction in PPARγ mRNA expression (P<0.001) in TDAG51−/− mouse embryonic fibroblasts (data not shown). Furthermore, siRNA knockdown of TDAG51 in HeLa cells also showed enhanced PPARγ expression (data not shown).

TDAG51 Deficiency Enhances PPARγ‐Dependent Inhibition of Inflammatory Cytokine Expression in Macrophages

Inflammation has been shown to modulate several processes that contribute to atherogenesis and lesion stability.33 TDAG51−/− peritoneal macrophages exhibited no basal differences in the expression of either MCP‐1 or TNFα relative to controls, as assessed by RT‐PCR (Figure 12A). However, in the presence of the PPARγ agonist rosiglitazone, TDAG51−/− macrophages expressed significantly lower levels of both MCP‐1 and TNFα, relative to wild‐type macrophages (Figure (Figure12A).12A). Furthermore, TDAG51 deficiency caused a significant reduction in LPS‐induced expression of MCP‐1 (22.4±0.8‐fold versus 31.6±1.5‐fold, P<0.05), but not TNF‐α, compared with wild‐type macrophages (Figure 12B). Human THP‐1‐derived macrophages, but not THP‐1 monocytes, as well as aortic endothelial cells (HAECs) and aortic smooth muscle cells (HASMCs), expressed TDAG51 protein (Figure 12C). Consistent with these findings, TDAG51 was also expressed in macrophages (CD68), smooth muscle cells (SMA), and endothelial cells (vWF) in lesions from human carotid arteries, as determined by dual immunohistochemistry (Figure 12D).

Figure 12.
TDAG51 deficiency increases rosiglitazone‐dependent inhibition of inflammatory marker expression in peritoneal macrophages. A, Peritoneal macrophages isolated from TDAG51−/− or C57BL/6 (C57) mice were incubated in the presence ...

Loss of TDAG51 Increases Cholesterol Efflux in Cultured Peritoneal Macrophages

Given that PPARγ increases reverse cholesterol transport in lesion‐resident macrophages and is considered atheroprotective,3738 we examined the effects of TDAG51 deficiency on macrophage foam cell formation and cholesterol efflux. To assess macrophage foam cell formation, peritoneal macrophages were cultured in the absence or presence of acetylated low‐density lipoprotein (LDL), and the accumulation of intracellular lipids was examined by ORO staining (Figure 13A). TDAG51−/− macrophages showed a significant reduction in ORO staining at 48 hours compared with wild‐type macrophages (Figure 13B). TDAG51−/− macrophages also accumulated significantly less cellular total cholesterol (1.8±0.1‐fold versus 3.1±0.1‐fold, P<0.05; Figure 13C) and free cholesterol (0.9±0.1‐fold versus 1.5±0.1‐fold, P<0.05; Figure 13D) after incubation with acetyl‐LDL (50 μg/mL) for 48 hours, relative to wild‐type macrophages. Consistent with the hypothesis that increased PPARγ results in reduced lipid accumulation, the PPARγ antagonist GW9662 (10 μmol/L) increased cellular total cholesterol in both wild‐type and KO macrophages after 48 hours incubation with 50 μg/mL acetyl‐LDL, compared with acetyl‐LDL treatment alone (Figure 13E). To determine whether the reduced lipid accumulation with TDAG51 deficiency was the result of increased cholesterol efflux, macrophages were loaded with [3H]cholesterol, and the percent change in intracellular radiolabeled cholesterol in the presence or absence of high‐density lipoprotein (HDL) was measured (Figure 13F). Cholesterol efflux was significantly increased in TDAG51−/− peritoneal macrophages 2, 3, and 5 hours after the addition of HDL, compared with WT macrophages (Figure 13F). PPARγ agonists induce the expression of ABCG1, a protein transporter mediating cholesterol efflux from macrophages.39 Consistent with these results, ABCG1 mRNA expression, but not ABCA1 expression, was significantly increased in TDAG51−/− peritoneal macrophages compared with wild‐type macrophages (Figure 11). Taken together, these results suggest the cumulative effect of increased cholesterol efflux over time leads to significantly lower intracellular total and free cholesterol levels in TDAG51−/− macrophages.

Figure 13.
Lipid accumulation and cholesterol efflux in TDAG51−/− peritoneal macrophages. A, Representative images from 3 independent experiments of Oil Red O (ORO) staining of C57BL/6 (C57) or TDAG51−/− macrophages treated with acetylated ...

Effect of TDAG51 Deficiency on Peroxiredoxin 1 Expression

Recent studies have suggested that loss of peroxiredoxin 1 (Prdx‐1), a member of a ubiquitous family of antioxidant enzymes,40 reduces endothelial cell activation and early atherosclerosis.41 Because an increase in Prdx‐1 expression could contribute to the observed cytoprotective effect of TDAG51 deficiency against oxidative stress (Figure 9B), lesions from dKO and ApoE−/− mice were immunostained for Prdx‐1. At both 25 (36.4% versus 8.4%, P=0.10) and 40 (31.3% versus 11.2%, P=0.15) weeks, the percentage of Prdx‐1 immunopositivity in the endothelium was increased in dKO mice compared with ApoE−/− controls (Figure 14A and and14B).14B). Furthermore, when mice from 25 and 40 weeks were combined, dKO mice exhibited significantly more Prdx‐1 immunopositivity than ApoE−/− mice (33.2% versus 10.1%, P=0.015; Figure 14C). In addition, TDAG51−/− peritoneal macrophages (Figure 14D) as well as lung microvascular endothelial cells (Figure 15A) exhibited increased Prdx‐1 protein expression. This correlated with a significant decrease in superoxide levels at basal conditions and improved resistance to 7‐ketocholesterol‐induced oxidative stress (Figures (Figures9B,9B, B,14E,14E, and and15B).15B). A significant increase in Prdx‐1 protein was also observed in TDAG51−/− peritoneal macrophages (2.7±0.4‐fold, P<0.05) following treatment with the PPARγ agonist rosiglitazone, compared with wild‐type cells (1.2±0.1‐fold, P<0.05; Figure 14F). Rosiglitazone treatment also induced Prdx‐1 protein expression in microvascular endothelial cells, although no significant differences were observed between TDAG51−/− and wild‐type cells (Figure 15A). Although TDAG51−/− mouse aortic smooth muscle cells also exhibited increased resistance to oxidative stress‐induced cell death in vitro (Figure 16), no differences in lesion smooth muscle cell apoptosis were observed in vivo (Figure 9A).

Figure 14.
TDAG51 deficiency increases Prdx‐1 expression in atherosclerotic lesions and reduces intracellular superoxide levels in TDAG51−/− peritoneal macrophages. TDAG51−/−/ApoE−/− (dKO) or ApoE−/− ...
Figure 15.
Prdx‐1 expression in TDAG51−/− mouse lung endothelial cells. A, Mouse lung endothelial cells (MLECs) from C57BL/6 (C57) or TDAG51−/− mice were treated in the presence or absence of 20 μmol/L rosiglitazone ...
Figure 16.
TDAG51 deficiency protects vascular smooth muscle cells (VSMCs) against endoplasmic reticulum (ER) and oxidative stress. VSMCs isolated from C57BL/6 (C57), TDAG51+/−, and TDAG51−/− mice were incubated in the presence or absence ...

Single‐Nucleotide Polymorphisms in the Human TDAG51 Gene Are Associated With CVD

The WTCCC case–control study of CVD published data for 5 single‐nucleotide polymorphisms (SNPs) in the 56‐kbp region that included the TDAG51 gene.30 Two of these SNPs (rs10880022 and rs2367446) were associated with CVD in this study (Table 3); both remained significant after Bonferroni correction for testing 5 SNPs. We genotyped rs10880022 and rs2367446 in the UCSF study31 and found that rs2367446 was also associated with myocardial infarction (OR, 1.24; 95% CI, 1.04 to 1.48; P=0.019). A combined analysis of rs2367446 in both studies found that it was associated with CVD, with an odds ratio of 1.15 (95% CI, 1.07 to 1.24, P=0.00031; Table 4); this P value remained significant after Bonferroni correction for testing 5 SNPs.

Table 3.
Association of SNPs in the TDAG51 Region With Myocardial Infarction in the WTCCC Study
Table 4.
Association of rs2367446 With CVD

Discussion

Several lines of evidence suggest that TDAG51 modulates lesion progression and plaque stability. First, TDAG51 is expressed in athero‐prone vascular endothelial cells19 as well as lesion‐resident macrophages and endothelial cells from ApoE−/− mice with diet‐induced hyperhomocysteinemia.6,15 Second, TDAG51 is expressed in apoptotic cells within the lipid‐rich necrotic core.6,15 Third, overexpression of TDAG51 in cultured human vascular endothelial cells leads to detachment‐induced apoptosis.15,34 Additional observations of increased TDAG51 expression during all stages of atherogenesis in the absence of HHcy6 suggest that other pathophysiological conditions that induce ER stress and/or TDAG51 expression modulate lesion growth and stability. In support of this hypothesis, we have reported that peroxynitrite, a proatherogenic agent generated from nitric oxide and superoxide, induces ER stress, TDAG51 expression, and apoptosis in cultured vascular endothelial cells.16 Given that ER stress plays a major role in lesion progression and plaque stability57,543 and that TDAG51 is an ER stress‐inducible gene6,1416 expressed in lesion resident macrophages and endothelial cells, we sought to investigate the causal role of TDAG51 in atherogenesis.

In this study, TDAG51−/−/ApoE−/− dKO male mice showed significant reductions in lesion and necrotic lipid core sizes in aortic roots at 25 and 40 weeks compared with age‐matched ApoE−/− controls. Thus, in the setting of a normal chow diet, ApoE−/− mice lacking TDAG51 exhibited reduced growth of atherosclerotic lesions.

As TDAG51 is expressed in lesion‐resident cells undergoing apoptotic cell death,6,15 a potential mechanism through which TDAG51 deficiency contributes to the reduced atherosclerotic lesion size and necrosis observed in this study is decreased lesional apoptosis. Decreased lesional necrosis from dKO mice was associated with reduced apoptosis, as determined by immunohistochemical staining for TUNEL and cleaved caspase‐3. Our data are consistent with the hypothesis that retardation of the rate of necrotic core and lesion growth is in part a consequence of increased resistance to macrophage cell death resulting from TDAG51 deficiency. Consistent with this hypothesis, peritoneal macrophages isolated from TDAG51−/− mice were resistant to ER and oxidative stress‐induced cell death. Cytoprotection was associated with increased levels of Prdx‐1 in lesions of dKO mice as well as in TDAG51−/− macrophages and endothelial cells. This was accompanied by reduced superoxide levels in TDAG51−/− macrophages at both baseline and when exposed to oxidative stress, a finding consistent with previous studies.4445 These data suggest that the elevation of Prdx‐1 levels associated with TDAG51 deficiency contributes to increased resistance to oxidative stress‐induced apoptosis, thereby reducing atherosclerotic lesion progression and rupture. This is consistent with the finding that Prdx‐1 deficiency in ApoE−/− mice causes endothelial activation (increased leukocyte rolling, endothelial P‐selectin, and vWF expression) and accelerates atherosclerosis.41 Further studies should clarify whether TDAG51‐mediated endothelial dysfunction contributes to atherogenesis.

It has been previously reported that inhibiting macrophage apoptosis increases atherosclerotic lesion size. Macrophage‐specific deletion of the proapoptotic gene p53 resulted in significantly increased lesion area after 15 or 20 weeks on a high‐fat diet in LDLR−/− mice.46 However, the authors attributed the larger lesion size to increased cell proliferation rather than decreased apoptosis, as no significant differences in apoptosis were observed. Liu et al11 demonstrated that macrophage‐specific deletion of Bax, a proapoptotic protein, decreased macrophage apoptosis and was associated with increased lesion area in LDLR−/− mice after 10 weeks on a Western diet. Alternatively, deletion of the macrophage apoptosis inhibitory factor (AIM) was associated with increased apoptosis and smaller lesion area in LDLR−/− mice after 5 or 12 weeks on a Western diet.47 Given the variability in genetic mouse models, diets used, and stage of atherosclerosis examined, a direct comparison to the current study is not possible. However, in the current study, in which lesions were assessed in dKO mice on a chow diet at later times (25 and 40 weeks) than the above studies (5 to 20 weeks on high‐fat or Western diets), data are consistent with the hypothesis that elevated macrophage apoptosis leads to reduced atherosclerosis at early stages and increased atherosclerosis at later stages of lesion growth. Furthermore, given that the model used in our study was global ablation of the TDAG51 gene, the observed reduction in lesion size may not be solely attributable to decreased macrophage apoptosis; other cell types and mechanisms may be involved.

Previous studies have indicated that PPARγ acts as a positive regulator of antioxidant defenses.48 Consistent with the inverse correlation between TDAG51 deficiency and PPARγ expression, rosiglitazone treatment induced Prdx‐1 protein expression by 23% (P<0.05) in TDAG51−/− macrophages, compared with 12% (P<0.05) in wild‐type macrophages (Figure 14F). These findings are consistent with previous studies showing that 15d‐PGJ2, a natural PPARγ agonist, induces expression of antioxidant proteins including Prdx‐149 and supports the hypothesis that the increased Prdx‐1 expression associated with TDAG51 deficiency is a consequence of elevated expression and/or activity of PPARγ, leading to the reduced atherosclerotic lesion growth observed in the dKO mice. Given the ability of TDAG51 to modulate transcriptional activity,13 we are currently investigating the possibility that TDAG51 modulates PPARγ transcriptional activity and/or nuclear localization.

It is well established that PPARγ activates reverse cholesterol transport in lesion‐resident macrophages.3738 Furthermore, PPARγ ligands promote the reduction of atherosclerotic lesions,5051 whereas the conditional knockout of macrophage PPARγ enhances atherosclerosis without altering plasma lipid levels.52 We observed increased cholesterol efflux as well as increased expression of ABCG1 in TDAG51−/− peritoneal macrophages. TDAG51−/− macrophages, compared with wild‐type cells, also accumulated fewer lipids, suggesting a reduction in foam cell formation. We recently reported that TDAG51 deficiency induced age‐associated adipogenesis and hepatic steatosis in TDAG51−/− mice,18 further implicating PPARγ in modulating the effects of TDAG51 deficiency. Taken together, our results suggest that TDAG51 deficiency, despite its effects on adipogenesis and hepatic lipogenesis, reduces atherosclerotic lesion growth via activation of multiple cellular pathways that regulate apoptosis, antioxidant status, and lipid storage/export.

Although studies reporting the beneficial role of PPARγ agonists in mitigating atherogenesis have been fairly consistent in mouse models, some controversy exists over the cardiovascular risk associated with the use of thiazolidinediones (TZDs) in patients. Several reports have indicated rosiglitazone is associated with significantly increased risk of myocardial infarction.5354 In contrast, others have found the evidence for an association between rosiglitazone and myocardial infarction and CVD mortality to be inconclusive.55 Furthermore, pioglitazone, another PPARγ agonist, was reported to have significantly reduced cardiovascular risk in the PROactive study in diabetic patients with preexisting CVD.56 Given the current debate over the potential beneficial and adverse events associated with TZDs in regard to CVD risk, it remains to be determined whether increased PPARγ associated with TDAG51 deficiency and decreased atherosclerotic lesion growth in a mouse model can be extrapolated to a clinical setting. It should also be noted that this mechanism is likely not the only one that drives the antiatherogenic effect of TDAG51 deficiency. This could reflect TDAG51's role in apoptosis or signaling pathways that modulate macrophage viability and lipid metabolism.

The genetic association results from 2 independent case–control studies31,30 suggest that genetic variants in the TDAG51 region are associated with CVD. This finding is intriguing given the biological evidence for this gene in atherosclerosis. However, meta‐analyses of genomewide association studies5758 did not find an association between SNPs in the TDAG51 region and CVD at the genomewide significance level (P<5×10−8). Therefore, the genetic association results we report here may have overestimated the risk associated with the SNPs we examined. Additional studies are thus required to further evaluate whether genetic variations in the TDAG51 gene are associated with altered expression of this gene and CVD. Functional characterization of these SNPs will also be helpful to understand the potential role of these SNPs in CVD. Because rs2367446 is in an intergenic region 20 kbp from TDAG51, it is possible that this SNP affects transcription of the TDAG51 gene.

In summary, we have characterized a previously unknown role for TDAG51 in modulating atherosclerotic lesion development and progression while addressing the underlying cellular mechanisms by which TDAG51 deficiency modulates these processes. Because the effects of TDAG51 are mediated by multiple pathways that affect lesion development and stability, our findings provide a unique opportunity to develop novel therapeutic approaches that decrease the risk of CVD by targeting TDAG51 expression and/or activity.

Source of Funding

This work was supported, in part, by research grants to Richard C. Austin from the Heart and Stroke Foundation of Ontario (PRG‐6502), the Canadian Institutes of Health Research (MOP‐126083, MOP‐111239), and the Ontario Research and Development Challenge Fund. Financial support from St. Joseph's Healthcare Hamilton is acknowledged. Jeffrey G. Dickhout is supported by the St. Joseph's Healthcare Hamilton Division of Nephrology Junior Research Award. Richard C. Austin is a Career Investigator of the Heart and Stroke Foundation of Ontario and holds the Amgen Canada Research Chair in the Division of Nephrology at St. Joseph's Healthcare and McMaster University.

Disclosures

None.

Acknowledgments

We thank the members of the Austin laboratory for their help during completion of this research project as well as expert technical assistance from Hansa Patel. TDAG51 heterozygous mice were kindly provided by Dr Y. Choi, University of Pennsylvania.

References

1. Lloyd‐Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation. 2010; 121:1768-1777. [PubMed]
2. Lusis AJ. Atherosclerosis. Nature. 2000; 407:233-241. [PMC free article] [PubMed]
3. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011; 145:341-355. [PMC free article] [PubMed]
4. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995; 91:2703-2711. [PubMed]
5. Thorp E, Li G, Seimon TA, Kuriakose G, Ron D, Tabas I. Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of ApoE−/− and Ldlr−/− mice lacking chop. Cell Metab. 2009; 9:474-481. [PMC free article] [PubMed]
6. Zhou J, Lhotak S, Hilditch BA, Austin RC. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E‐deficient mice. Circulation. 2005; 111:1814-1821. [PubMed]
7. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX, Kuriakose G, Fisher EA, Marks AR, Ron D, Tabas I. The endoplasmic reticulum is the site of cholesterol‐induced cytotoxicity in macrophages. Nat Cell Biol. 2003; 5:781-792. [PubMed]
8. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008; 28:2108-2114. [PubMed]
9. Wilson KM, McCaw RB, Leo L, Arning E, Lhotak S, Bottiglieri T, Austin RC, Lentz SR. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE‐deficient mice. Arterioscler Thromb Vasc Biol. 2007; 27:233-240. [PubMed]
10. Mackman N, Taubman M. Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol. 2009; 29:1986-1988. [PMC free article] [PubMed]
11. Liu J, Thewke DP, Su YR, Linton MF, Fazio S, Sinensky MS. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low‐density lipoprotein receptor‐null mice. Arterioscler Thromb Vasc Biol. 2005; 25:174-179. [PMC free article] [PubMed]
12. Boesten LS, Zadelaar AS, van Nieuwkoop A, Hu L, Jonkers J, van de Water B, Gijbels MJ, van der Made I, de Winther MP, Havekes LM, van Vlijmen BJ. Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE‐deficient mice. FASEB J. 2006; 20:953-955. [PubMed]
13. Park CG, Lee SY, Kandala G, Choi Y. A novel gene product that couples TCR signaling to Fas(CD95) expression in activation‐induced cell death. Immunity. 1996; 4:583-591. [PubMed]
14. Joo JH, Liao G, Collins JB, Grissom SF, Jetten AM. Farnesol‐induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. Cancer Res. 2007; 67:7929-7936. [PubMed]
15. Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E, Poddar R, Jacobsen DW, Zhang K, Kaufman RJ, Austin RC. TDAG51 is induced by homocysteine, promotes detachment‐mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem. 2003; 278:30317-30327. [PubMed]
16. Dickhout JG, Hossain GS, Pozza LM, Zhou J, Lhotak S, Austin RC. Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: implications in atherogenesis. Arterioscler Thromb Vasc Biol. 2005; 25:2623-2629. [PubMed]
17. Neef R, Kuske MA, Prols E, Johnson JP. Identification of the human PHLDA1/TDAG51 gene: down‐regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res. 2002; 62:5920-5929. [PubMed]
18. Basseri S, Lhotak S, Fullerton MD, Palanivel R, Jiang H, Lynn EG, Ford RJ, Maclean KN, Steinberg GR, Austin RC. Loss of TDAG51 results in mature‐onset obesity, hepatic steatosis, and insulin resistance by regulating lipogenesis. Diabetes. 2013; 62:158-169. [PMC free article] [PubMed]
19. Dai G, Kaazempur‐Mofrad MR, Natarajan S, Zhang Y, Vaughn S, Blackman BR, Kamm RD, Garcia‐Cardena G, Gimbrone MA., Jr Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis‐susceptible and ‐resistant regions of human vasculature. Proc Natl Acad Sci USA. 2004; 101:14871-14876. [PubMed]
20. Rho J, Gong S, Kim N, Choi Y. TDAG51 is not essential for Fas/CD95 regulation and apoptosis in vivo. Mol Cell Biol. 2001; 21:8365-8370. [PMC free article] [PubMed]
21. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992; 258:468-471. [PubMed]
22. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator‐activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor‐deficient mice. J Clin Invest. 2000; 106:523-531. [PMC free article] [PubMed]
23. Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, Tipping P, Bobik A, Toh BH. Depletion of B2 but not B1a B cells in BAFF receptor‐deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS ONE. 2012; 7:e29371. [PMC free article] [PubMed]
24. Marelli‐Berg FM, Peek E, Lidington EA, Stauss HJ, Lechler RI. Isolation of endothelial cells from murine tissue. J Immunol Methods. 2000; 244:205-215. [PubMed]
25. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37:911-917. [PubMed]
26. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. The fatty acid‐binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator‐activated receptor gamma and IkappaB kinase activities. J Biol Chem. 2005; 280:12888-12895. [PMC free article] [PubMed]
27. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA. 1997; 94:12610-12615. [PubMed]
28. Zhou J, Moller J, Danielsen CC, Bentzon J, Ravn HB, Austin RC, Falk E. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE‐deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21:1470-1476. [PubMed]
29. Lhotak S, Zhou J, Austin RC. Immunohistochemical detection of the unfolded protein response in atherosclerotic plaques. Methods Enzymol. 2011; 489:23-46. [PubMed]
30. Wellcome Trust Case Control Consortium Genome‐wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447:661-678. [PMC free article] [PubMed]
31. Shiffman D, Kane JP, Louie JZ, Arellano AR, Ross DA, Catanese JJ, Malloy MJ, Ellis SG, Devlin JJ. Analysis of 17,576 potentially functional SNPs in three case‐control studies of myocardial infarction. PLoS ONE. 2008; 3:e2895. [PMC free article] [PubMed]
32. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet‐induced type II diabetes in C57BL/6J mice. Diabetes. 1988; 37:1163-1167. [PubMed]
33. Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54:2129-2138. [PMC free article] [PubMed]
34. Hayashida N, Inouye S, Fujimoto M, Tanaka Y, Izu H, Takaki E, Ichikawa H, Rho J, Nakai A. A novel HSF1‐mediated death pathway that is suppressed by heat shock proteins. EMBO J. 2006; 25:4773-4783. [PubMed]
35. Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, Fazio S, Wiest MM, Watkins SM, Linton MF, Hotamisligil GS. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009; 15:1383-1391. [PMC free article] [PubMed]
36. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998; 93:241-252. [PubMed]
37. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR gamma‐LXR‐ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001; 7:161-171. [PubMed]
38. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR‐alpha and PPAR‐gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001; 7:53-58. [PubMed]
39. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam‐cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest. 2004; 114:1564-1576. [PMC free article] [PubMed]
40. Lim MJ, Chae HZ, Rhee SG, Yu DY, Lee KK, Yeom YI. The type II peroxiredoxin gene family of the mouse: molecular structure, expression and evolution. Gene. 1998; 216:197-205. [PubMed]
41. Kisucka J, Chauhan AK, Patten IS, Yesilaltay A, Neumann C, Van Etten RA, Krieger M, Wagner DD. Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circ Res. 2008; 103:598-605. [PubMed]
42. Zhou J, Werstuck GH, Lhotak S, de Koning AB, Sood SK, Hossain GS, Moller J, Ritskes‐Hoitinga M, Falk E, Dayal S, Lentz SR, Austin RC. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E‐deficient mice. Circulation. 2004; 110:207-213. [PubMed]
43. Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ Res. 2010; 107:839-850. [PMC free article] [PubMed]
44. Conway JP, Kinter M. Dual role of peroxiredoxin I in macrophage‐derived foam cells. J Biol Chem. 2006; 281:27991-28001. [PubMed]
45. Schreibelt G, van Horssen J, Haseloff RF, Reijerkerk A, van der Pol SM, Nieuwenhuizen O, Krause E, Blasig IE, Dijkstra CD, Ronken E, de Vries HE. Protective effects of peroxiredoxin‐1 at the injured blood‐brain barrier. Free Radic Biol Med. 2008; 45:256-264. [PubMed]
46. Merched AJ, Williams E, Chan L. Macrophage‐specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol. 2003; 23:1608-1614. [PubMed]
47. Arai S, Shelton JM, Chen M, Bradley MN, Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ, Tontonoz P, Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 2005; 1:201-213. [PubMed]
48. Chung SS, Kim M, Youn BS, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM, Lee HK, Park KS. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator‐activated receptor gamma in human skeletal muscle cells. Mol Cell Biol. 2009; 29:20-30. [PMC free article] [PubMed]
49. Itoh K, Mochizuki M, Ishii Y, Ishii T, Shibata T, Kawamoto Y, Kelly V, Sekizawa K, Uchida K, Yamamoto M. Transcription factor NRF2 regulates inflammation by mediating the effect of 15‐deoxy‐delta(12,14)‐prostaglandin J(2). Mol Cell Biol. 2004; 24:36-45. [PMC free article] [PubMed]
50. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor‐deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21:365-371. [PubMed]
51. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E‐knockout mice: pleiotropic effects on CD36 expression and hdl. Arterioscler Thromb Vasc Biol. 2001; 21:372-377. [PubMed]
52. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low‐density lipoprotein receptor‐deficient mice. Arterioscler Thromb Vasc Biol. 2005; 25:1647-1653. [PubMed]
53. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2471. [PubMed]
54. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta‐analysis of observational studies. BMJ. 2011; 342:d1309. [PMC free article] [PubMed]
55. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007; 147:578-581. [PubMed]
56. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. PROactive investigators Safety and tolerability of pioglitazone in high‐risk patients with type 2 diabetes: an overview of data from proactive. Drug Saf. 2009; 32:187-202. [PubMed]
57. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Cardiogenics. Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J, CARDIoGRAM Consortium. Samani NJ. Large‐scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011; 43:333-338. [PMC free article] [PubMed]
58. Coronary Artery Disease Genetics Consortium A genome‐wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011; 43:339-344. [PubMed]

Articles from Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease are provided here courtesy of Wiley-Blackwell